Utah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million

Reuters

14 hours ago

Utah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million

Utah Medical Products published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting worldwide revenues of USD 38.5 million, down 5.8%.
Net income was USD 11.29 million, down 18.7%, while diluted EPS was USD 3.48, down 12.1%.
Operating income was USD 11.4 million, down 16.1%, and gross profit was USD 22 million, down 8.9%.
Management attributed the revenue decline mainly to lower PendoTECH OEM sales, lower Deltran DPT distributor sales in China, and lower worldwide Filshie sales.
For 2026, management expects consolidated sales to be about the same as 2025 and projects operating income to increase 15%-18%, citing anticipated gross margin expansion and Femcare identifiable intangible asset amortization ending after 1Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Utah Medical Products Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001096906-26-000395), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622058068"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622058068\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622058068?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622058068","market":"nz","top_or_hot":-1,"title":"Utah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Utah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Utah Medical Products published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025, reporting worldwide revenues of USD 38.5 million, down 5.8%.\n        </li>\n<li>\n          Net income was USD 11.29 million, down 18.7%, while diluted EPS was USD 3.48, down 12.1%.\n        </li>\n<li>\n          Operating income was USD 11.4 million, down 16.1%, and gross profit was USD 22 million, down 8.9%.\n        </li>\n<li>\n          Management attributed the revenue decline mainly to lower PendoTECH OEM sales, lower Deltran DPT distributor sales in China, and lower worldwide Filshie sales.\n        </li>\n<li>\n          For 2026, management expects consolidated sales to be about the same as 2025 and projects operating income to increase 15%-18%, citing anticipated gross margin expansion and Femcare identifiable intangible asset amortization ending after 1Q 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Utah Medical Products Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001096906-26-000395), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Utah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUtah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 05:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Utah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Utah Medical Products published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025, reporting worldwide revenues of USD 38.5 million, down 5.8%.\n        </li>\n<li>\n          Net income was USD 11.29 million, down 18.7%, while diluted EPS was USD 3.48, down 12.1%.\n        </li>\n<li>\n          Operating income was USD 11.4 million, down 16.1%, and gross profit was USD 22 million, down 8.9%.\n        </li>\n<li>\n          Management attributed the revenue decline mainly to lower PendoTECH OEM sales, lower Deltran DPT distributor sales in China, and lower worldwide Filshie sales.\n        </li>\n<li>\n          For 2026, management expects consolidated sales to be about the same as 2025 and projects operating income to increase 15%-18%, citing anticipated gross margin expansion and Femcare identifiable intangible asset amortization ending after 1Q 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Utah Medical Products Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001096906-26-000395), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTMD","symbol_name":"犹他医疗产品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL88J9tc:1","article_id":"2622058068","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622058068","pubTimestamp":1774646670,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Utah Medical Products published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting worldwide revenues of USD 38.5 million, down 5.8%.Net income was USD 11.29 million, down 18.7%, while diluted EPS was USD 3.48, down 12.1%.Operating income was USD 11.4 million, down 16.1%, and gross profit was USD 22 million, down 8.9%.For 2026, management expects consolidated sales to be about the same as 2025 and projects operating income to increase 15%-18%, citing anticipated gross margin expansion and Femcare identifiable intangible asset amortization ending after 1Q 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Utah Medical Products Inc. published the original content used to generate this news brief via EDGAR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTMD":"犹他医疗产品","BK4198":"医疗保健用品"},"translate_title":"犹他州医疗产品2025财年营业收入下降16.1%至1140万美元；收入下降5.8%至3850万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTMD":0.9},"content_text":"Utah Medical Products FY2025 operating income drops 16.1% to $11.4 million; revenue falls 5.8% to $38.5 million\n    \n\n\n          Utah Medical Products published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting worldwide revenues of USD 38.5 million, down 5.8%.\n        \n\n          Net income was USD 11.29 million, down 18.7%, while diluted EPS was USD 3.48, down 12.1%.\n        \n\n          Operating income was USD 11.4 million, down 16.1%, and gross profit was USD 22 million, down 8.9%.\n        \n\n          Management attributed the revenue decline mainly to lower PendoTECH OEM sales, lower Deltran DPT distributor sales in China, and lower worldwide Filshie sales.\n        \n\n          For 2026, management expects consolidated sales to be about the same as 2025 and projects operating income to increase 15%-18%, citing anticipated gross margin expansion and Femcare identifiable intangible asset amortization ending after 1Q 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Utah Medical Products Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001096906-26-000395), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}